Molecular Diagnostics News and Research

RSS

Co-Diagnostics awarded patent related to its CoPrimer platform technology

Co-Diagnostics, Inc., a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, announced today that it has been awarded a patent from the United States Patent and Trademark Office related to the Company's CoPrimer™ platform technology.

10 Oct 2018

New blood test may detect early-stage lung cancer when surgical intervention is not possible

Non-small-cell lung carcinoma is often fatal because most cases are not diagnosed until they are so advanced that surgical intervention is no longer possible. To improve outcomes researchers are developing a blood test to detect lung cancer earlier in the disease.

8 Oct 2018

NorthShore and Ambry announce launch of new test to assess prostate cancer risk

NorthShore University HealthSystem's Center for Personalized Medicine and Ambry Genetics Corporation, announced today the launch of AmbryScore for prostate cancer risk.

26 Sep 2018

QIAGEN and DiaSorin launch automated, CE-marked workflow for high-throughput TB screening

QIAGEN N.V. and DiaSorin today announced the introduction of an automated, CE-marked workflow for QIAGEN’s QuantiFERON-TB Gold Plus Blood Collection Tubes (QFT-Plus BCT) and a novel DiaSorin LIAISON Test on widely used immunodiagnostic instruments from DiaSorin.

17 Sep 2018

New assay using cellphone cameras developed for testing mosquitos, Wolbachia

Wolbachia bacteria are widely studied for possible properties to block transmission of viruses like chikungunya, dengue and zika.

31 Aug 2018

New assay may help improve both sarcoma diagnosis and treatment

Sarcomas are rare tumors that are often misdiagnosed. Specific recurrent chromosomal rearrangements, known as translocations, can serve as essential diagnostic markers and are found in about 20 percent of sarcomas.

20 Aug 2018

FIND and genedrive announce study agreement to evaluate HCV ID Kit

genedrive plc, a near patient molecular diagnostics company, and the Foundation for Innovation of New Diagnostics (FIND), announced today a study agreement for the performance evaluation of genedrive plc’s hepatitis C virus (HCV) Genedrive HCV ID Kit.

10 Aug 2018

Two new studies could improve treatment for patients with diabetes

Researchers have developed a novel test that rapidly distinguishes between type 1 and type 2 diabetes. This new method and a second study revealing gaps in care for women with gestational diabetes were presented today at the 70th AACC Annual Scientific Meeting & Clinical Lab Expo, and could improve treatment for patients with all diabetes types across the board.

1 Aug 2018

Vitamin D supplementation could significantly improve quality of life for RA patients

Scientists have discovered that in rheumatoid arthritis patients, lower levels of vitamin D are associated with increased disease severity.

1 Aug 2018

Research: Two out of three at-home ovulation tests do not provide accurate results

Research announced today at the 70th AACC Annual Scientific Meeting & Clinical Lab Expo reveals that two out of three of the digital home ovulation tests sold by U.S. retailers do not accurately predict when a woman is ovulating.

31 Jul 2018

Co-Diagnostics obtains CE mark approval for Logix Smart MTB Test

Co-Diagnostics, Inc., a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, announced today that its Logix Smart™ MTB Test has obtained CE mark approval, the principle regulatory clearance allowing the test to be sold as an in vitro diagnostic for the diagnosis of tuberculosis in European Union states and other markets that accept a CE-IVD mark as valid regulatory approval.

25 Jul 2018

Study: Blood test can predict response of advanced prostate cancer patients to treatments

An international collaborative study between Lawson Health Research Institute, Memorial Sloan Kettering Cancer Center, the Royal Marsden and Epic Sciences is one of the first to demonstrate that a blood test can predict how patients with advanced prostate cancer will respond to specific treatments, leading to improved survival.

25 Jul 2018

OGT announces direct sales and support services in Europe

Oxford Gene Technology, The Molecular Genetics Company, has announced that it is now directly selling Cytocell Fluorescence In Situ Hybridisation products through several established affiliates of SysmexCorporation in Europe following its acquisition last year.

From Oxford Gene Technology 4 Jul 2018

Innovative concept for implementing WHO resolution to safeguard quality of cancer treatment

Cancer is a burden to those affected by it and a growing challenge to the political sector. In 2017, WHO therefore issued an international resolution to safeguard the quality of cancer treatment, and access to it, in every country in the world.

14 Jun 2018

Agendia and Angsana partner to market MammaPrint, BluePrint breast cancer tests in Southeast Asia

Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, and Angsana Molecular & Diagnostics Laboratory Pte Ltd, a subsidiary of Parkway Pantai, announce a partnership to market the MammaPrint Breast Cancer Risk of Recurrence test and the BluePrint Molecular Subtyping test to physicians across Southeast Asia, including Singapore, Malaysia, Vietnam, Brunei and Myanmar.

31 May 2018

Study identifies new biomarker for early lung cancer diagnosis

High levels of cytoskeleton-associated protein 4 (CKAP4) have been identified in the blood of patients with lung cancer.

8 May 2018

New data supports clinical use of DecisionDx-Melanoma test to inform SLNB options

Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer treatment decisions, today announced the presentation of data supporting clinical use of the DecisionDx®-Melanoma test to inform sentinel lymph node biopsy (SLNB) recommendations.

7 May 2018

Tradeshow Talks with Molbio Diagnostics Ltd

Tradeshow Talks with Molbio Diagnostics Ltd at Health GB 2018.

7 May 2018

New, sensitive HBV assay may allow earlier detection of hepatocellular carcinoma

Chronic hepatitis B virus (HBV) can progress to cirrhosis and hepatocellular carcinoma (HCC). A study published in The Journal of Molecular Diagnostics describes a new HBV assay that offers advantages over currently used methods because it has the capability to detect closed circular DNA (cccDNA) in serum, single cells, and preserved tissue samples.

12 Apr 2018

Oxford Gene Technology announces leadership changes

Oxford Gene Technology, The Molecular Genetics Company, has announced that on 1st April 2018 Dr John Anson who has been with the company since 2006 as EVP of R&D took over as CEO from Dr Mike Evans, who has become a non-executive director of OGT’s board.

From Oxford Gene Technology 10 Apr 2018